Lenalidomide in Combination With Bendamustine and Rituximab for Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma(CLL/SLL): a Phase I Study
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 23 Jun 2017
At a glance
- Drugs Lenalidomide (Primary) ; Bendamustine; Rituximab
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- 17 Dec 2016 Planned End Date changed from 1 Nov 2013 to 1 Dec 2018.
- 17 Dec 2016 Planned primary completion date changed from 1 Nov 2014 to 1 Dec 2017.
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.